Parkinson’s disease, treatment choice and survival over time
Objectives: We compared Monoamine oxidase B (MAO-B) – and dopamine agonist (DA) monotherapy patients with respect to survival, considering gender, age, first prescriber’s specialty and relevant co-morbidity, and compared their specialist health care contacts and hospitalizations. Methods: With data...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Clinical Parkinsonism & Related Disorders |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S259011252200007X |
| _version_ | 1811242713805225984 |
|---|---|
| author | I.F. Tvete M. Klemp |
| author_facet | I.F. Tvete M. Klemp |
| author_sort | I.F. Tvete |
| collection | DOAJ |
| description | Objectives: We compared Monoamine oxidase B (MAO-B) – and dopamine agonist (DA) monotherapy patients with respect to survival, considering gender, age, first prescriber’s specialty and relevant co-morbidity, and compared their specialist health care contacts and hospitalizations. Methods: With data from health registries, we considered 21,047 patients without redemptions for MAO-B, DA or levodopa 6 months prior to their first MAO-B or DA redemption in 2006 and followed them throughout 2016. We considered Cox proportional hazard regression models for comparing the risk of death among MAO-B and DA monotherapy patients. Results: MAO-B-users had a higher mortality than DA-users, [HR: 1.587, 95% CI: 1.056; 2.384] for patients under 74 years. There was an increased mortality risk with increasing age, women had lower risk than men and previous diabetes-, antihypertensive-, and cardiac drug users had higher risk compared to patients without such history. Previous use of hypothyroid drugs and having a specialist as first prescriber were not significant risk factors.Among patients without hospitalizations 13.7% died, while among patients who spent at least one night in hospital 36.73% died. The median duration of a hospitalization among those who died and not were 17.5 and 7 days. Among the small proportion with specialist health care contacts circulatory- and respiratory-system diseases were the most frequent cause of contact. Conclusions: DAs were most frequently given when initiating Parkinson’s treatment. DA-users had a lower mortality risk compared to MAO-B-users and less specialist health care contact. |
| first_indexed | 2024-04-12T13:54:58Z |
| format | Article |
| id | doaj.art-82bbee33743e457899df5d0dea0a8627 |
| institution | Directory Open Access Journal |
| issn | 2590-1125 |
| language | English |
| last_indexed | 2024-04-12T13:54:58Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical Parkinsonism & Related Disorders |
| spelling | doaj.art-82bbee33743e457899df5d0dea0a86272022-12-22T03:30:24ZengElsevierClinical Parkinsonism & Related Disorders2590-11252022-01-016100136Parkinson’s disease, treatment choice and survival over timeI.F. Tvete0M. Klemp1The Norwegian Computing Center, Oslo, Norway; Corresponding author.Department of Pharmacology, University of Oslo, Oslo, NorwayObjectives: We compared Monoamine oxidase B (MAO-B) – and dopamine agonist (DA) monotherapy patients with respect to survival, considering gender, age, first prescriber’s specialty and relevant co-morbidity, and compared their specialist health care contacts and hospitalizations. Methods: With data from health registries, we considered 21,047 patients without redemptions for MAO-B, DA or levodopa 6 months prior to their first MAO-B or DA redemption in 2006 and followed them throughout 2016. We considered Cox proportional hazard regression models for comparing the risk of death among MAO-B and DA monotherapy patients. Results: MAO-B-users had a higher mortality than DA-users, [HR: 1.587, 95% CI: 1.056; 2.384] for patients under 74 years. There was an increased mortality risk with increasing age, women had lower risk than men and previous diabetes-, antihypertensive-, and cardiac drug users had higher risk compared to patients without such history. Previous use of hypothyroid drugs and having a specialist as first prescriber were not significant risk factors.Among patients without hospitalizations 13.7% died, while among patients who spent at least one night in hospital 36.73% died. The median duration of a hospitalization among those who died and not were 17.5 and 7 days. Among the small proportion with specialist health care contacts circulatory- and respiratory-system diseases were the most frequent cause of contact. Conclusions: DAs were most frequently given when initiating Parkinson’s treatment. DA-users had a lower mortality risk compared to MAO-B-users and less specialist health care contact.http://www.sciencedirect.com/science/article/pii/S259011252200007X |
| spellingShingle | I.F. Tvete M. Klemp Parkinson’s disease, treatment choice and survival over time Clinical Parkinsonism & Related Disorders |
| title | Parkinson’s disease, treatment choice and survival over time |
| title_full | Parkinson’s disease, treatment choice and survival over time |
| title_fullStr | Parkinson’s disease, treatment choice and survival over time |
| title_full_unstemmed | Parkinson’s disease, treatment choice and survival over time |
| title_short | Parkinson’s disease, treatment choice and survival over time |
| title_sort | parkinson s disease treatment choice and survival over time |
| url | http://www.sciencedirect.com/science/article/pii/S259011252200007X |
| work_keys_str_mv | AT iftvete parkinsonsdiseasetreatmentchoiceandsurvivalovertime AT mklemp parkinsonsdiseasetreatmentchoiceandsurvivalovertime |